These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26523442)

  • 1. Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002.
    Vargas CE; Hartsell WF; Dunn M; Keole SR; Doh L; Eisenbeisz E; Larson GL
    Am J Clin Oncol; 2018 Feb; 41(2):115-120. PubMed ID: 26523442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002.
    Vargas CE; Hartsell WF; Dunn M; Keole SR; Doh L; Chang J; Larson GL
    Rep Pract Oncol Radiother; 2016; 21(3):207-12. PubMed ID: 27601952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
    Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
    Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.
    Nakajima K; Iwata H; Ogino H; Hattori Y; Hashimoto S; Nakanishi M; Toshito T; Umemoto Y; Iwatsuki S; Shibamoto Y; Mizoe JE
    Int J Clin Oncol; 2018 Apr; 23(2):353-360. PubMed ID: 29098520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer.
    Vargas CE; Schmidt MQ; Niska JR; Hartsell WF; Keole SR; Doh L; Chang JH; Sinesi C; Rodriquez R; Pankuch M; Larson GL
    Adv Radiat Oncol; 2018; 3(3):322-330. PubMed ID: 30202801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Clinical Safety of High-Dose Proton Radiation Therapy Delivered With Pencil Beam Scanning Technique for Extracranial Chordomas and Chondrosarcomas in Adult Patients: Clinical Evidence of Spinal Cord Tolerance.
    Stieb S; Snider JW; Placidi L; Kliebsch U; Lomax AJ; Schneider RA; Weber DC
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):218-225. PubMed ID: 29029887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
    Ödén J; Eriksson K; Toma-Dasu I
    Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
    Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
    de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound.
    Holtzman AL; Hoppe BS; Letter HP; Bryant C; Nichols RC; Henderson RH; Mendenhall WM; Morris CG; Williams CR; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):465-471. PubMed ID: 26883560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial.
    Murakami M; Ishikawa H; Sekino Y; Nishiyama H; Suzuki H; Sugahara S; Iizumi T; Mizumoto M; Okumura T; Keino N; Iizumi Y; Hashimoto K; Gosho M; Sakurai H
    J Radiat Res; 2024 May; 65(3):402-407. PubMed ID: 38739903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Mutter RW; Giri S; Fruth BF; Remmes NB; Boughey JC; Harless CA; Ruddy KJ; McGee LA; Afzal A; Gao RW; Shumway DA; Vern-Gross TZ; Villarraga HR; Kenison SL; Kang Y; Wong WW; Stish BJ; Merrell KW; Yan ES; Park SS; Corbin KS; Vargas CE
    Lancet Oncol; 2023 Oct; 24(10):1083-1093. PubMed ID: 37696281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.